Meeting NewsVideo

VIDEO: HemOnc Today Chief Medical Editors discuss key takeaways from ASCO Annual Meeting

CHICAGO — Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, and John Sweetenham, MD, FRCP, FACP, Chief Medical Editors of HemOnc Today, discuss key studies and themes from the ASCO Annual Meeting.

Sweetenham offered perspective on the long-term follow-up of a study designed to evaluate rituximab (Rituxan; Genentech, Biogen) in patients with lymphoma, in which the drug failed to improve survival compared with standard of care.

In addition, he reviewed the study designed to evaluate larotrectinib (LOXO-101, Loxo Oncology) — the first selective small-molecule pan-tropomyosin receptor kinase inhibitor — which demonstrated clinical activity in adults and children with various tumors that had neurotrophic tyrosine receptor kinase gene fusions.

Raghavan discussed two studies designed to evaluate the impact of abiraterone (Zytiga, Janssen Oncology) on survival in advanced prostate cancer.

“This year, there have been a series of papers that question if you abiraterone prednisone to androgen suppression, does that improve outcome?” Raghavan said. – by Kristie L. Kahl

Disclosure: Raghavan and Sweetenham report no relevant financial disclosures.

CHICAGO — Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, and John Sweetenham, MD, FRCP, FACP, Chief Medical Editors of HemOnc Today, discuss key studies and themes from the ASCO Annual Meeting.

Sweetenham offered perspective on the long-term follow-up of a study designed to evaluate rituximab (Rituxan; Genentech, Biogen) in patients with lymphoma, in which the drug failed to improve survival compared with standard of care.

In addition, he reviewed the study designed to evaluate larotrectinib (LOXO-101, Loxo Oncology) — the first selective small-molecule pan-tropomyosin receptor kinase inhibitor — which demonstrated clinical activity in adults and children with various tumors that had neurotrophic tyrosine receptor kinase gene fusions.

Raghavan discussed two studies designed to evaluate the impact of abiraterone (Zytiga, Janssen Oncology) on survival in advanced prostate cancer.

“This year, there have been a series of papers that question if you abiraterone prednisone to androgen suppression, does that improve outcome?” Raghavan said. – by Kristie L. Kahl

Disclosure: Raghavan and Sweetenham report no relevant financial disclosures.

    See more from ASCO Annual Meeting